Abstract
1. Thermo Fisher Scientific Introduces Highly Sensitive Research Assays for Measurable Residual Disease Detection in Myeloid Malignancies
Thermo Fisher Scientific launched the Ion Torrent Oncomine Myeloid MRD Assays (RUO), the first NGS-based tests for research in myeloid measurable residual disease (MRD) to support both DNA and RNA input from blood and bone marrow samples.
Current methods for assessing MRD do not evaluate individual mutations or can only track a very limited number at once. The new Myeloid MRD Assays have been designed to enable simultaneous testing and identification of more than 90% of common AML mutations and fusions, providing insights to guide the future of clinical applications, standards and drug development.
2. MERSCOPE™, the First High Multiplexing, High Resolution in situ Platform to combine Single-Cell and Spatial Genomics
Vizgen is developing the next generation of genomic profiling tools that enable researchers to gain new insight into the biological systems that underlie human health and disease with spatial context. The MERSCOPETM Platform is the first high plex, in situ single-cell spatial genomics solution. MERSCOPE uses MERFISH technology to directly map and quantify the spatial distribution of hundreds to tens of thousands of RNA species in individual cells, without the need for downstream sequencing.
3. PGDx's FDA-cleared IVD kit empowers pathologists with scalable in-house genomic testing
Personal Genome Diagnostics Inc. (PGDx), now a part of Labcorp, is a leader in cancer genomics with a portfolio of in-house precision oncology solutions. The PGDx elio™ tissue complete test is the industry's first and only NGS diagnostic kit for comprehensive tumor profiling that is FDA cleared and CE-IVD marked for use in labs worldwide. The PGDx elio™ tissue complete test is covered by Medicare with a national reimbursement rate. This pan solid tumor CGP test identifies key genomic alterations and guideline supported biomarkers in 500+ genes and is backed by robust and automated bioinformatics, empowering timely and trustworthy results.
4. ANGLE plc launches FDA cleared Parsortix PC1 Clinical System
ANGLE, a leader in liquid biopsy, launched its patented Parsortix® PC1 Clinical System, the first FDA cleared medical device for the capture and harvest of intact circulating tumor cells (CTCs) from metastatic breast cancer (MBC) patient blood for subsequent, user-validated analysis. The ability to monitor and analyze CTCs may transform the treatment of MBC, providing patients with personalized cancer care through a non-invasive, repeat liquid biopsy with the power of Parsortix® technology.
Contact us at